Scavenger Receptors and Their Potential as Therapeutic Targets in the Treatment of Cardiovascular Disease

被引:62
|
作者
Stephen, Sam L. [1 ]
Freestone, Katie [1 ]
Dunn, Sarah [1 ]
Twigg, Michael W. [1 ,2 ]
Homer-Vanniasinkam, Shervanthi [1 ,2 ]
Walker, John H. [1 ]
Wheatcroft, Stephen B. [3 ]
Ponnambalam, Sreenivasan [1 ]
机构
[1] Univ Leeds, Inst Mol & Cellular Biol, Endothelial Cell Biol Unit, LIGHT Labs, Clarendon Way, Leeds LS2 9JT, W Yorkshire, England
[2] Leeds Gen Infirm, Leeds Vasc Inst, Leeds LS1 3EX, W Yorkshire, England
[3] Univ Leeds, Fac Med & Hlth, Acad Unit Mol & Vasc Med, LIGHT Labs, Leeds LS2 9JT, W Yorkshire, England
关键词
D O I
10.4061/2010/646929
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Scavenger receptors act as membrane-bound and soluble proteins that bind to macromolecular complexes and pathogens. This diverse supergroup of proteins mediates binding to modified lipoprotein particles which regulate the initiation and progression of atherosclerotic plaques. In vascular tissues, scavenger receptors are implicated in regulating intracellular signaling, lipid accumulation, foam cell development, and cellular apoptosis or necrosis linked to the pathophysiology of atherosclerosis. One approach is using gene therapy to modulate scavenger receptor function in atherosclerosis. Ectopic expression of membrane-bound scavenger receptors using viral vectors can modify lipid profiles and reduce the incidence of atherosclerosis. Alternatively, expression of soluble scavenger receptors can also block plaque initiation and progression. Inhibition of scavenger receptor expression using a combined gene therapy and RNA interference strategy also holds promise for long-termtherapy. Here we review our current understanding of the gene delivery by viral vectors to cells and tissues in gene therapy strategies and its application to the modulation of scavenger receptor function in atherosclerosis.
引用
收藏
页数:21
相关论文
共 50 条
  • [31] Peroxisome prolliferator-activated receptors: Potential therapeutic targets in lung disease?
    Denning, GM
    Stoll, LL
    PEDIATRIC PULMONOLOGY, 2006, 41 (01) : 23 - 34
  • [32] Nonalcoholic fatty liver disease: Pathogenesis and potential for nuclear receptors as therapeutic targets
    George, Jacob
    Liddle, Christopher
    MOLECULAR PHARMACEUTICS, 2008, 5 (01) : 49 - 59
  • [33] Leukotrienes:: potential therapeutic targets in cardiovascular diseases
    Back, Magnus
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2006, 190 (07): : 1511 - 1518
  • [34] Peptidyl-prolyl isomerases: Functionality and potential therapeutic targets in cardiovascular disease
    Rostam, Muhamad A.
    Piva, Terrence J.
    Rezaei, Hossein B.
    Kamato, Danielle
    Little, Peter J.
    Zheng, Wenhua
    Osman, Narin
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2015, 42 (02) : 117 - 124
  • [35] Role of Treg cell subsets in cardiovascular disease pathogenesis and potential therapeutic targets
    Xia, Yuanliang
    Gao, Di
    Wang, Xu
    Liu, Bin
    Shan, Xue
    Sun, Yunpeng
    Ma, Dashi
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [36] Scavenger receptors: targets for antiplatelet therapies?
    Gawaz, Meinrad
    BLOOD, 2008, 111 (04) : 1749 - 1750
  • [37] The leukotriene receptors as therapeutic targets of inflammatory disease
    Sasaki, Fumiyuki
    Yokomizo, Takehiko
    INTERNATIONAL IMMUNOLOGY, 2019, 31 (09) : 607 - 615
  • [38] Toll-like receptors as a potential therapeutic target for atherosclerosis and cardiovascular disease
    Lacheta, Dominika
    Olejarz, Wioletta
    Wrzosek, Malgorzata
    Nowicka, Grazyna
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2018, 72 : 728 - 739
  • [39] Peroxiredoxins as Potential Targets for Cardiovascular Disease
    Jeong, Se-Jin
    Park, Jong-Gil
    Oh, Goo Taeg
    ANTIOXIDANTS, 2021, 10 (08)
  • [40] Nuclear receptors as therapeutic targets in the treatment of atherosclerosis
    Wright, S
    ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (02) : 182 - 182